DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...

Pfizer’s JAK/TEC inhibitor Litfulo has been recommended for NHS use as a treatment for hair loss caused by severe alopecia areata, the first drug therapy for a condition that affects around ...

Pfizer said that Litfulo (ritlecitinib) is the first alopecia areata therapy to be cleared for use in adolescents in the EU. JAK1/2 inhibitor Olumiant (baricitinib) was the first drug to be ...

A man suffering alopecia says he is being denied a groundbreaking new drug – despite it being approved. The daily pill, ...

Pfizer is currently assessing the potential divestiture of its hospital drugs unit, a division mainly focused on antibiotics and sterile injectables used in hospitals and clinics, Reuters reported.

JAK inhibitors like baricitinib, ritlecitinib, and brepocitinib show promise in treating alopecia areata, with baricitinib ...

Credit: Pfizer. Pfizer is currently assessing the potential divestiture of its hospital drugs unit, a division mainly focused on antibiotics and sterile injectables used in hospitals and clinics, ...

Hair loss is considered widespread in recent years and has many degrees, as it begins with hair loss and may eventually lead to complete hair loss. There are many causes, the most important of which ...

The ‘140 patent expires in June 2031, according to Inlyta’s entry in the US Food and Drug Administration’s registry of approved drugs, the Orange Book. Pfizer seeks orders blocking copies until then.